San Francisco VA Medical Center, and Department of Medicine, University of California San Francisco, San Francisco, California, USA.
J Am Geriatr Soc. 2010 Apr;58(4):650-7. doi: 10.1111/j.1532-5415.2010.02769.x.
Although osteoporosis treatment can dramatically reduce fracture risk, rates of treatment after hip fracture remain low. In-hospital initiation of recommended medications has improved outcomes in heart disease; hospitalization for hip fracture may represent a similar opportunity for improvement. The objective of this study was to examine rates of in-hospital treatment with a combination of calcium and vitamin D (Cal+D) and antiresorptive or bone-forming medications in patients hospitalized for hip fractures
Observational cohort.
Three hundred eighteen hospitals in the United States.
Fifty-one thousand three hundred forty-six patients aged 65 and older hospitalized for osteoporotic hip fracture.
In-hospital administration of Cal+D and antiresorptive or bone-forming medications.
Three thousand four hundred five patients (6.6%) received Cal+D anytime after a procedure to correct femoral fracture; 3,763 patients (7.3%) received antiresorptive or bone-forming medications. Only 1,023 patients (2.0%) were prescribed ideal therapy, receiving Cal+D and an antiresorptive or bone-forming medication. Treatment rates remained low across virtually all patient-, provider-, and hospital-level characteristics. The strongest predictor of treatment with Cal+D was the receipt of an antiresorptive or bone-forming medication (adjusted odds ratio=5.50, 95% confidence interval=4.84-6.25), but only 27.2% of patients who received these medications also received Cal+D.
Rates of in-hospital initiation of osteoporosis treatment for patients with hip fracture are low and may represent an opportunity to improve care.
尽管骨质疏松症治疗可以显著降低骨折风险,但髋部骨折后的治疗率仍然较低。在心脏病患者中,住院时开始使用推荐药物已改善了治疗效果;髋部骨折住院可能代表了改善治疗的类似机会。本研究的目的是检查因骨质疏松性髋部骨折住院的患者中,联合使用钙和维生素 D(Cal+D)以及抗吸收或成骨药物的住院治疗率。
观察性队列研究。
美国 318 家医院。
51346 名年龄在 65 岁及以上的因骨质疏松性髋部骨折住院的患者。
住院期间给予 Cal+D 和抗吸收或成骨药物的情况。
3405 名患者(6.6%)在进行纠正股骨骨折的手术后的任何时间接受了 Cal+D;3763 名患者(7.3%)接受了抗吸收或成骨药物治疗。仅有 1023 名患者(2.0%)接受了理想的治疗,即同时接受了 Cal+D 和抗吸收或成骨药物治疗。在几乎所有患者、医生和医院层面的特征中,治疗率仍然很低。接受 Cal+D 的最强预测因素是接受抗吸收或成骨药物治疗(调整后的优势比=5.50,95%置信区间=4.84-6.25),但仅 27.2%接受这些药物治疗的患者也同时接受了 Cal+D。
髋部骨折患者住院时开始骨质疏松症治疗的比率较低,这可能代表改善治疗的机会。